PIK3CA and breast cancer: Considering the adjuvant setting, biomarker analysis of the FinHER [56] and of the NSABP-B31 [57] did not show significant interaction between PIK3CA status and trastuzumab benefit, nor differences in DFS among PIK3CA wild-type or mutant BC [58].